Evidence map›Paper›PMID 41933183›Full record

ArticleNature cancer2026

PRET is a few-shot system for pan-cancer recognition without example training.

Yi Li, Ziyu Ning, Tianqi Xiang, Qixiang Zhang, Zhihao Lin, Min Yi, Feiyan Feng, Baozhen Zeng, Xuexia Qian, Lu Sun and 10 more

Abstract read
PubMed Publisher
In one paragraph

Article in Nature cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Yi Li *Department of Electronic and Computer Engineering, The Hong Kong University of Science and Technology, Hong Kong SAR, China.
Ziyu Ning *Department of Pathology, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China.
Tianqi XiangDepartment of Electronic and Computer Engineering, The Hong Kong University of Science and Technology, Hong Kong SAR, China.ORCID http://orcid.org/0000-0002-5550-1721
Qixiang ZhangDepartment of Electronic and Computer Engineering, The Hong Kong University of Science and Technology, Hong Kong SAR, China.
Zhihao LinDepartment of Pathology, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China.
Min YiDepartment of Pathology, the Fifth People's Hospital of Qinghai Province, Qinghai Province Cancer Hospital, Xining, China.
Feiyan FengDepartment of Pathology, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China.
Baozhen ZengDepartment of Pathology, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China.
Xuexia QianDepartment of Pathology, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China.
Lu SunDepartment of Pathology, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China.
Jiace QinDepartment of Pathology, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China.
Ling XiangDepartment of Pathology, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China.
Chao FanDepartment of Pathology, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China.
Tian QinDepartment of Pathology, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China.
Qian WangDepartment of Pathology, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China.
Xiu-Wu BianInstitute of Pathology and Southwest Cancer Center, the First Affiliated Hospital (Southwest Hospital) and School of Basic Medical Sciences, Army Medical University (Third Military Medical University) and the Key Laboratory of Tumor Immunopathology, The Ministry of Education (Third Military Medical University), Chongqing, China.ORCID http://orcid.org/0000-0003-4383-0197
Kun-Hsing YuDepartment of Biomedical Informatics, Harvard Medical School, Boston, MA, USA.ORCID http://orcid.org/0000-0001-9892-8218
Kang ZhangInstitute for AI in Medicine, Faculty of Medicine, Macau University of Science and Technology, Macau SAR, China. kang.zhang@gmail.com.ORCID http://orcid.org/0000-0002-4549-1697
Qingling ZhangDepartment of Pathology, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China. zhangqingling@gdph.org.cn.ORCID http://orcid.org/0000-0002-5287-264X
Xiaomeng LiDepartment of Electronic and Computer Engineering, The Hong Kong University of Science and Technology, Hong Kong SAR, China. eexmli@ust.hk.ORCID http://orcid.org/0000-0003-1105-8083

Funding

Robust, Generalizable, and Fair Machine Learning Models for BiomedicineR35GM142879 · NIGMS · HARVARD MEDICAL SCHOOL · PI YU, KUN-HSING · 2021 to 2025
$2.4M
Mitigating Hematologic Adverse Events in Patients with Myeloid Malignancies: A Novel Causal Artificial Intelligence ApproachR01HL174679 · NHLBI · HARVARD MEDICAL SCHOOL · PI Kun-Hsing Yu · 2024 to 2026
$2.3M
National Natural Science Foundation of China (National Science Foundation of China) No. 62306254National Natural Science Foundation of China (National Science Foundation of China) No. 82173033National Natural Science Foundation of China (National Science Foundation of China) W2431057Research Grants Council, University Grants Committee (RGC, UGC) AoE/E-601/24-NResearch Grants Council, University Grants Committee (RGC, UGC) N_HKUST654/24Research Grants Council, University Grants Committee (RGC, UGC) R6005-24Research Grants Council, University Grants Committee (RGC, UGC) T45-401/22-NU.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute (NHLBI) R01HL174679U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences (NIGMS) R35GM142879
6 · The paper itself

Abstract

Pathological examination stands as the cornerstone in cancer diagnosis, impacting millions worldwide annually. With the shortage of pathologists globally, artificial intelligence (AI) has emerged rapidly to automate the diagnostics process. However, conventional AI models require substantial labeled data for each disease, posing huge challenges in scalability and practicality. Therefore, we introduce PRET (pan-cancer recognition without examples training), a few-shot system to achieve flexible, scalable, and effective cancer recognition across diverse organs, hospitals and tasks without training. Evaluated on 23 international benchmarks comprising 4,484 whole-slide images, our method outperforms existing approaches across 20 tasks, achieving over 97% area under the curve on 15 benchmarks with a maximum improvement of 36.76%. Notably, PRET delivers clinical-grade diagnostic performance in lymph node metastasis detection using only eight slide examples, outperforming 11 pathologists. By offering a flexible and cost-effective solution for pan-cancer recognition, PRET paves the way for accessible and equitable AI-based pathology systems, particularly benefiting minority populations and underserved regions.

Indexed as

Artificial IntelligenceImage Interpretation, Computer-AssistedNeoplasmsHumansIntelligent Systems

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.